CD8A and neoplasm: As noted above, D-2HG also impacts immunoregulatory functions in tumour activity, as it is released by tumour cells in the interstitial space within the tumour microenvironment, causing it to accumulate and then taken up by T lymphocytes, ultimately compromising their capacity to mediate anticancer immune responses, impairing CD8+ T-cell proliferation and cytotoxic capacity.17–20